Company ProfilePremium

Lonza

Company Profile Analysis

ESOMAR 23 Corporate BadgeISO Certifications Badge
Lonza - Healthcare showcase

Year Founded & Workforce

1897

15,500 Employees

Industry

Healthcare

Services

Viral Therapy
L

Lonza Employee Contacts

766 verified contactsNames, job titles, seniority and locations

View Employee Contacts

Lonza Overview

Company Headquarters: Basel, Switzerland

Founded: 1897

Workforce: 15,500+

Company Working:

Lonza is a well-known brand in the global pharmaceutical market and it is involved in manufacturing and marketing of products related to the biotechnology, pharmaceuticals, and nutraceuticals sector. The company operates in business segments including Pharmaceutical ingredients, Custom manufacturing, Personal Care, Bioscience, Biopharmaceuticals, Biotechnology, Life science ingredients, Agriculture, Nutrition, Microbial Control, and Materials Science. It also has a strong research and development department which is equipped with prominent scientists, alongside advanced machinery. The company is present in more than 100 countries and has strong presence in all the major markets.

Strategy

Lonza is focusing on development of pharmaceutical and biotechnological business and divesting unnecessary product portfolios. Also, the company is focused on adopting to any technological changes and developing innovative products for the betterment of the people. It believes in achieving continuum (Pharma & Biotech, Consumer Health,

and Consumer & Resources Protection), which refers to the creation of a healthy environment, promoting a healthier lifestyle, preventing illness to improving patient healthcare. Moreover, the company is active and involved in various merger and acquisition and emphasizes on achieving organic growth. For instance, in July 2017, the company acquired Capsugel for USD 5500 million and became major supplier in the pharmaceutical, biotech and specialty ingredients markets. Lonza is present in all the established markets and has wide product portfolio which provides competitive advantage over other market players.

Lonza carries out manufacturing of viral vector products in Houston based production plant. The company follows cGMP guidelines and produces viral vaccine, viral vector biologics, and viral immunotherapies.

It uses following technologies in manufacturing process:

· Single-use bioreactor technologies with capacity up to 2000 L

· Depth filtration

· Large-scale ultra/diafiltration

· Large-scale chromatographic purification

· Ultracentrifugation

· Adherent and suspension cell culture systems

Company Snapshot

15,500

Employees

1897

Founded

Basel, Switzerland

Headquarters

Product Offering

  • Lonza
    • Viral Therapy

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.